To answer some of these questions, prospective studies evaluating in newly diagnosed CP CML patients, the dynamics of PB CD26+ LSCs during different TKI treatment, as well as studies monitoring PB CD26+ LSCs prospectively in CML patients that discontinued TKIs, are currently ongoing. Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.